(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Tornier N.V., Aileron Therapeutics, and Albireo Pharma.

Rank Financial Asset Price Change Updated (EST)
1 Tornier N.V. (TRNX) 0.00 166.67% 2022-04-05 19:13:06
2 Aileron Therapeutics (ALRN) 0.69 9.52% 2022-04-06 15:47:16
3 Albireo Pharma (ALBO) 35.39 8.13% 2022-04-06 15:10:07
4 Atrion (ATRI) 753.90 5.46% 2022-04-06 14:38:50
5 Eli Lilly and Company (LLY) 305.93 4.6% 2022-04-06 14:59:32
6 NRG Energy (NRG) 39.29 4.45% 2022-04-06 14:48:40
7 Exelon (EXC) 49.74 4.07% 2022-04-06 14:54:35
8 Antero Resources (AR) 31.62 3.96% 2022-04-06 14:55:53
9 Alberton Acquisition Corporation (ALACW) 0.26 3.92% 2022-04-06 15:09:06
10 Aeglea BioTherapeutics (AGLE) 2.62 3.56% 2022-04-06 13:08:06

The three most active and biggest losers today are Senmiao Technology Limited, ViacomCBS, and AIkido Pharma.

Rank Financial Asset Price Change Updated (EST)
1 Senmiao Technology Limited (AIHS) 1.64 -23.52% 2022-04-06 13:14:12
2 ViacomCBS (VIAC) 29.58 -17.81% 2022-04-06 09:49:27
3 AIkido Pharma (AIKI) 0.41 -11.69% 2022-04-06 13:15:13
4 FuboTV (FUBO) 6.20 -10.33% 2022-04-06 14:56:12
5 Accolade (ACCD) 16.05 -9.42% 2022-04-06 10:23:14
6 Celsius Holdings (CELH) 51.55 -9.18% 2022-04-06 14:49:56
7 LendingTree (TREE) 113.39 -9.06% 2022-04-06 14:59:56
8 Cloudflare (NET) 109.70 -8.92% 2022-04-06 14:56:44
9 Veracyte (VCYT) 27.01 -8.5% 2022-04-06 01:12:06
10 ADiTx Therapeutics (ADTX) 0.43 -8.32% 2022-04-06 11:12:05

Most Active Winners today

1. Tornier N.V. (TRNX) – 166.67%

Taronis Technologies, Inc. is a technology-based firm that focuses on the challenges of natural resources, with a primary focus on the United States. MagneGas is a hydrogen-based, synthetic fuel used to replace acetylene or other natural gas derived fuels. It can also be used for other industrial uses such as metal cutting. The company also offers Plasma Arc flow system for MagneGas production or water sterilization. The company also licenses its plasma arc technology, which is used for liquid waste processing and gasification. The company distributes MagneGas gas, as well as other supplies and gases through retailers. The business was formerly called MagneGas Applied Technology Solutions, Inc., and it changed its name in January 2019 to Taronis Technologies, Inc. Taronis Technologies, Inc. is located in Peoria, Arizona.

NASDAQ ended the session with Tornier N.V. jumping 166.67% to $0.00 on Wednesday while NASDAQ slid 2.22% to $13,888.82.

Volume

Today’s last reported volume for Tornier N.V. is 3063 which is 95.08% below its average volume of 62333.

Tornier N.V.’s last close was $0.00, 97.79% below its 52-week high of $0.04.

Tornier N.V.’s Sales

Tornier N.V.’s sales growth is 148.6% for the ongoing quarter and 126% for the next.

Tornier N.V.’s Revenue

Year-on-year quarterly revenue growth grew by 104.7%, now sitting on 19.17M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Tornier N.V.’s stock is considered to be oversold (<=20).

Tornier N.V.’s Moving Average

Tornier N.V.’s value is below its 50-day moving average of $0.00 and under its 200-day moving average of $0.01.

More news about Tornier N.V..

2. Aileron Therapeutics (ALRN) – 9.52%

Aileron Therapeutics, Inc. is a US-based clinical stage oncology company. ALRN-6924 is currently in phase 1 for solid tumor and lymphoma. Phase 2a clinical trials are underway to treat peripheral lymphoma. Phase 1b is a trial that will test ALRN-6924 with Cytarabine or Ara-C in MDS patients. Phase 2a is a trial to combine ALRN-6924 with palbociclib for MDM2 co-amplifications in MDM2 tumors. Phase 1b has concluded. Aileron Therapeutics, Inc. is licensed to Harvard College and Dana-Farber Cancer Institute. Umicore Precious Metals Chemistry USA, LLC has also been approved. The original name of the company was Renegade Therapeutics, Inc., but it changed its name in February 2007 to Aileron Therapeutics, Inc. Aileron Therapeutics, Inc., was founded in 2001. It is located in Boston, Massachusetts.

NASDAQ ended the session with Aileron Therapeutics jumping 9.52% to $0.69 on Wednesday while NASDAQ fell 2.22% to $13,888.82.

Volume

Today’s last reported volume for Aileron Therapeutics is 1299380 which is 249.57% above its average volume of 371698.

Aileron Therapeutics’s last close was $0.63, 55.63% below its 52-week high of $1.42.

The company’s growth estimates for the present quarter is 33.3% and a drop 25% for the next.

Aileron Therapeutics’s Stock Yearly Top and Bottom Value

Aileron Therapeutics’s stock is valued at $0.69 at 17:32 EST, way under its 52-week high of $1.42 and way above its 52-week low of $0.36.

Aileron Therapeutics’s Moving Average

Aileron Therapeutics’s worth is way higher than its 50-day moving average of $0.45 and way below its 200-day moving average of $0.79.

More news about Aileron Therapeutics.

3. Albireo Pharma (ALBO) – 8.13%

Albireo Pharma, Inc. is a biopharmaceutical firm that focuses on developing and commercializing novel bile acid modators for the treatment of orphan liver disorders and other liver and gastrointestinal disorders. Odevixibat is the company’s leading product candidate. It is currently in phase 3 clinical trials for treating patients suffering from progressive familial intrahepatic cholesterol. Elobixibat is being developed by the company for chronic constipation, other functional disorders and nonalcoholicsteatohepatitis. EA Pharma Co., Ltd. has granted it a license to develop and market elobixibat. Boston is the headquarters of this company.

NASDAQ ended the session with Albireo Pharma jumping 8.13% to $35.39 on Wednesday while NASDAQ slid 2.22% to $13,888.82.

Volume

Today’s last reported volume for Albireo Pharma is 361142 which is 29.4% above its average volume of 279080.

Albireo Pharma’s last close was $32.73, 13.55% under its 52-week high of $37.86.

Albireo Pharma’s Sales

Albireo Pharma’s sales growth is 371% for the present quarter and 488.4% for the next. The company’s growth estimates for the current quarter and the next is 21.8% and 10%, respectively.

Albireo Pharma’s Revenue

Year-on-year quarterly revenue growth grew by 1097.4%, now sitting on 40.58M for the twelve trailing months.

Albireo Pharma’s Stock Yearly Top and Bottom Value

Albireo Pharma’s stock is valued at $35.39 at 17:32 EST, below its 52-week high of $37.86 and way above its 52-week low of $20.30.

Albireo Pharma’s Moving Average

Albireo Pharma’s worth is way higher than its 50-day moving average of $30.49 and way above its 200-day moving average of $29.22.

More news about Albireo Pharma.

4. Atrion (ATRI) – 5.46%

Atrion Corporation designs, produces, and markets products for fluid delivery and cardiovascular applications. Fluid delivery products are valves that hold and control fluid flow and gasses. They can be used in anesthesia, oncology, intubation and intravenous catheter applications. MPS2 Myocardial Safety System delivers fluids and medication, mixes crucial drugs and controls temperature and pressure; heart surgery vacuum relief valves; silicon vessel loops that retract and occlude vessels; inflation devices for balloon catheter dilation and stent deployment; fluid dispensing; as well as products designed for use during heart bypass surgery. The company’s ophthalmic products includes specialized medical devices to disinfect contact lenses and balloon catheters that are used in the treatment of nasolacrimal obstruction in both children and adults. Instrumentation, as well as associated disposables for measuring activated blood clotting times and safe scalpel and needle blade containment are also manufactured by the company. It also manufactures valves and inflation systems for marine and aviation safety; parts used in inflatable structures and survival products; pressure relief valves to protect delicate electronics and products that are used during transportation in non-medical and medical applications. It sells products to doctors, hospitals, clinics and other treatment centres. Atrion Corporation was established in 1944. It is located in Allen, Texas.

NASDAQ ended the session with Atrion rising 5.46% to $753.90 on Wednesday, following the last session’s upward trend. NASDAQ dropped 2.22% to $13,888.82, following the last session’s downward trend on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for Atrion is 5158 which is 15.05% above its average volume of 4483.

Atrion’s last close was $714.88, 11.26% below its 52-week high of $805.62.

Atrion’s Revenue

Year-on-year quarterly revenue growth grew by 26.8%, now sitting on 156.96M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Atrion’s stock is considered to be oversold (<=20).

Atrion’s Stock Yearly Top and Bottom Value

Atrion’s stock is valued at $753.90 at 17:32 EST, under its 52-week high of $805.62 and way higher than its 52-week low of $579.96.

Atrion’s Moving Average

Atrion’s value is way higher than its 50-day moving average of $679.93 and way above its 200-day moving average of $682.64.

More news about Atrion.

5. Eli Lilly and Company (LLY) – 4.6%

Eli Lilly and Company develops and manufactures pharmaceutical products around the world. The company offers diabetes products, osteoporosis for postmenopausal women as well as paediatric growth condition and human growth hormone deficiencies. It also offers neuroscience products to treat depressive disorder and diabetic peripheral neuropathy pain. It also offers products that treat ankylosing syndrome, rheumatoid, plaque psoriasis and psoriatica. Eli Lilly and Company has a number of collaborations, including with Pfizer Inc., Dicerna Pharmaceuticals, Inc., AC Immune SA, Centrexion Therapeutics Corporation, ImmuNext, Inc., Avidity Biosciences, Inc., and the Duke Clinical Research Institute to prevent and treat chronic heart failure and death after acute myocardial injury. There is also an agreement with Junshi Biosciences for co-development of therapeutic antibodies that could be used in the treatment and prevention of the novel coronavirus. It was established in Indianapolis in 1876.

NYSE ended the session with Eli Lilly and Company jumping 4.6% to $305.93 on Wednesday, after three sequential sessions in a row of gains. NYSE slid 0.35% to $16,587.10, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for Eli Lilly and Company is 3743730 which is 26.9% above its average volume of 2950120.

Eli Lilly and Company’s last close was $266.30, 9.83% below its 52-week high of $295.33.

Eli Lilly and Company’s Revenue

Year-on-year quarterly revenue growth grew by 18%, now sitting on 27.76B for the twelve trailing months.

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $305.93 at 17:32 EST, higher than its 52-week high of $295.33.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s value is way higher than its 50-day moving average of $258.47 and way above its 200-day moving average of $251.49.

More news about Eli Lilly and Company.

6. NRG Energy (NRG) – 4.45%

NRG Energy, Inc., along with its affiliates, is an American energy company. The company operates in two segments: Generation and Retail. It is engaged in producing, selling and delivering electricity to approximately 3.7 million commercial, residential and industrial customers. The company generates electricity from natural gas, coke, oil, natural gas, solar, nuclear, and battery storage. It also offers system power, distributed generator, renewable products and backup generation. Demand response, energy efficiency and advisory services are available. It also trades in natural gas and electric power. The company also procures fuels and provides transport services. It directly sells energy and services to customers, under NRG, Reliant Green Mountain Energy and Stream as well as products and services. It owns 23,000 megawatts of generation capacity, including nuclear and fossil fuel plants. NRG Energy, Inc., was established in 1989. It is located in Princeton, New Jersey.

NYSE ended the session with NRG Energy jumping 4.45% to $39.29 on Wednesday while NYSE fell 0.35% to $16,587.10.

Volume

Today’s last reported volume for NRG Energy is 2158180 which is 22.26% below its average volume of 2776340.

NRG Energy’s last close was $38.48, 16.53% below its 52-week high of $46.10.

NRG Energy’s Sales

NRG Energy’s sales growth is 65.3% for the present quarter and a decline by 43.5% for the next. The company’s growth estimates for the current quarter and the next is 90.1% and 306.1%, respectively.

NRG Energy’s Revenue

Year-on-year quarterly revenue growth grew by 135.3%, now sitting on 21.97B for the twelve trailing months.

NRG Energy’s Stock Yearly Top and Bottom Value

NRG Energy’s stock is valued at $39.29 at 17:32 EST, way under its 52-week high of $46.10 and way higher than its 52-week low of $31.94.

NRG Energy’s Moving Average

NRG Energy’s value is above its 50-day moving average of $38.48 and below its 200-day moving average of $40.18.

More news about NRG Energy.

7. Exelon (EXC) – 4.07%

Exelon Corporation is a holding company for utility services. It engages in energy generation, distribution, and marketing in both the United States of America and Canada. The company owns a variety of facilities, including solar, nuclear, renewable, energy, biofuel, wind and hydroelectric. It also offers electricity wholesale to retail customers and natural gas and renewable energy as well as other energy-related products, services, and goods. It is also involved in the regulation and purchase of natural gas and electricity; transmission and distribution, as well distribution of natural gas retail customers. The company also offers support services such as legal, human resource, information technology and accounting. The company serves residential, commercial, industrial and governmental customers as well as distribution utilities and cooperatives. It was founded in 1999 in Chicago, Illinois.

NASDAQ ended the session with Exelon rising 4.07% to $49.74 on Wednesday, after three sequential sessions in a row of gains. NASDAQ slid 2.22% to $13,888.82, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for Exelon is 9997380 which is 7.63% below its average volume of 10823800.

Exelon’s last close was $43.63, 9.16% under its 52-week high of $48.03.

Exelon’s Sales

Exelon’s sales growth is a negative 21% for the ongoing quarter and a decline by 0.3% for the next. The company’s growth estimates for the present quarter and the next is 15.8% and 1433.3%, respectively.

Exelon’s Revenue

Year-on-year quarterly revenue growth grew by 0.6%, now sitting on 34.83B for the twelve trailing months.

Exelon’s Stock Yearly Top and Bottom Value

Exelon’s stock is valued at $49.74 at 17:33 EST, above its 52-week high of $48.03.

Exelon’s Moving Average

Exelon’s value is way higher than its 50-day moving average of $43.00 and way above its 200-day moving average of $37.78.

More news about Exelon.

8. Antero Resources (AR) – 3.96%

Antero Resources Corporation is an independent oil-and-natural gas company that acquires, investigates, develops and produces natural gaz, natural gas liquids and other oil properties throughout the United States. The company owned approximately 451,000 acres of net land in the Marcellus Shale’s southwestern core and 91,000 acres of net land in the Utica Shale core as of December 31, 2019. The company also operated 324 mile of Marcellus Shale gas gathering pipelines, 17 compressor stations and 110 miles of Utica Shale low-pressure/high-pressure gathering pipelines. It also owns and operates 8 miles high-pressure pipelines and two compressor stations. It had proved natural gas reserves estimated at 18.9 trillion cubic yards, which included 11.5 trillion cubic meters of natural gas, 652 million barrels assumed-recovered ethane and 540 million barrels each of normal butane and propane; as well as 42 million barrels oil. Antero Resources Appalachian Corporation was the company’s former name. In June 2013, it changed its name from Antero Resources Corporation to Antero Resources Corporation. Antero Resources Corporation was established in 2002. It is located in Denver, Colorado.

NYSE ended the session with Antero Resources jumping 3.96% to $31.62 on Wednesday while NYSE dropped 0.35% to $16,587.10.

Volume

Today’s last reported volume for Antero Resources is 8066470 which is 8.63% below its average volume of 8829300.

Antero Resources’s last close was $26.67, 16.26% under its 52-week high of $31.85.

Antero Resources’s Sales

Antero Resources’s sales growth is 13.1% for the current quarter and 29.8% for the next. The company’s growth estimates for the current quarter and the next is 2833.3% and 96.8%, respectively.

Antero Resources’s Revenue

Year-on-year quarterly revenue growth grew by 99.2%, now sitting on 5.55B for the twelve trailing months.

Antero Resources’s Stock Yearly Top and Bottom Value

Antero Resources’s stock is valued at $31.62 at 17:33 EST, below its 52-week high of $31.85 and way higher than its 52-week low of $8.81.

Antero Resources’s Moving Average

Antero Resources’s value is way higher than its 50-day moving average of $23.57 and way above its 200-day moving average of $18.49.

More news about Antero Resources.

9. Alberton Acquisition Corporation (ALACW) – 3.92%

Alberton Acquisition Corporation has no significant operations. The company’s primary purpose is to enter into mergers, share-exchanges, asset acquisitions, stock purchases, recapitalizations, and other similar business combinations with target businesses. This company used to be called Wisdom Resources Group Limited. In July 2018, it changed its name from Alberton Acquisition Corporation. Alberton Acquisition Corporation was established in 2005. It is located in Wan Chai in Hong Kong.

NASDAQ ended the session with Alberton Acquisition Corporation jumping 3.92% to $0.26 on Wednesday while NASDAQ dropped 2.22% to $13,888.82.

Alberton Acquisition Corporation’s last close was $0.18, 38% below its 52-week high of $0.29.

Alberton Acquisition Corporation’s Stock Yearly Top and Bottom Value

Alberton Acquisition Corporation’s stock is valued at $0.26 at 17:33 EST, way under its 52-week high of $0.29 and higher than its 52-week low of $0.25.

More news about Alberton Acquisition Corporation.

10. Aeglea BioTherapeutics (AGLE) – 3.56%

Aeglea BioTherapeutics, Inc., is a biotech company in clinical stage. It designs and develops enzyme therapies for patients with rare metabolic disorders. Pegzilarginase is the company’s leading product candidate. This recombinant Arginase1 is currently in Phase III PEACE to assess its safety and effectiveness for treating Arginase 1. AGLE-177 is also being developed by the company. This Phase I/II clinical study is for patients with homocystinuria. The company also has research and cystinuria in its preclinical pipeline. The original name of the company was Aeglea BioTherapeutics Holdings, LLC. In March 2015, it changed its name from Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc., was established in 2013. It is located in Austin, Texas.

NASDAQ ended the session with Aeglea BioTherapeutics jumping 3.56% to $2.62 on Wednesday while NASDAQ fell 2.22% to $13,888.82.

Volume

Today’s last reported volume for Aeglea BioTherapeutics is 189215 which is 38.42% below its average volume of 307278.

Aeglea BioTherapeutics’s last close was $2.53, 70.85% below its 52-week high of $8.68.

The company’s growth estimates for the ongoing quarter and the next is a negative 21.4% and a negative 240%, respectively.

Aeglea BioTherapeutics’s Stock Yearly Top and Bottom Value

Aeglea BioTherapeutics’s stock is valued at $2.62 at 17:33 EST, way under its 52-week high of $8.68 and way higher than its 52-week low of $1.80.

Aeglea BioTherapeutics’s Moving Average

Aeglea BioTherapeutics’s worth is way below its 50-day moving average of $3.00 and way under its 200-day moving average of $5.59.

More news about Aeglea BioTherapeutics.

Most Active Losers Today

1. Senmiao Technology Limited (AIHS) – -23.52%

Senmiao Technology Limited is involved in automobile transactions and related services in China. The company facilitates automobile transactions and financing. It connects ride-hailing drivers with financial institutions in order to finance or buy cars that will be used for ride-hailing. It also offers auto financing services and automobile sales. Senmiao Technology is a strategic partner with Gaode Map to use ride-sharing initiatives. Senmiao Technology Limited, which was established in 2017, is located in Chengdu in the People’s Republic of China.

NASDAQ ended the session with Senmiao Technology Limited falling 23.52% to $1.64 on Wednesday, following the last session’s downward trend. NASDAQ slid 2.22% to $13,888.82, following the last session’s downward trend on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for Senmiao Technology Limited is 782071 which is 29.87% above its average volume of 602165.

Senmiao Technology Limited’s last close was $0.22, 89.71% below its 52-week high of $2.09.

Senmiao Technology Limited’s Revenue

Year-on-year quarterly revenue growth grew by 105.4%, now sitting on 8.33M for the twelve trailing months.

Senmiao Technology Limited’s Stock Yearly Top and Bottom Value

Senmiao Technology Limited’s stock is valued at $1.64 at 17:33 EST, way below its 52-week high of $2.09 and way above its 52-week low of $0.16.

Senmiao Technology Limited’s Moving Average

Senmiao Technology Limited’s value is way above its 50-day moving average of $0.28 and way above its 200-day moving average of $0.54.

More news about Senmiao Technology Limited.

2. ViacomCBS (VIAC) – -17.81%

NASDAQ ended the session with ViacomCBS sliding 17.81% to $29.58 on Wednesday while NASDAQ dropped 2.22% to $13,888.82.

Volume

Today’s last reported volume for ViacomCBS is 87514000 which is 461.24% above its average volume of 15592900.

ViacomCBS’s last close was $36.84, 63.87% below its 52-week high of $101.97.

The company’s growth estimates for the ongoing quarter and the next is a negative 16.5% and a negative 30.8%, respectively.

ViacomCBS’s Revenue

Year-on-year quarterly revenue growth grew by 13.2%, now sitting on 27.46B for the twelve trailing months.

ViacomCBS’s Stock Yearly Top and Bottom Value

ViacomCBS’s stock is valued at $29.58 at 17:33 EST, way below its 52-week high of $101.97 and above its 52-week low of $28.90.

ViacomCBS’s Moving Average

ViacomCBS’s worth is way under its 50-day moving average of $35.62 and way under its 200-day moving average of $43.11.

More news about ViacomCBS.

3. AIkido Pharma (AIKI) – -11.69%

AIkido Pharma Inc. is a biotechnology firm that focuses on the development of small-molecule anticancer therapies. The company’s therapeutic pipeline includes treatments for acute myeloid and pancreatic cancers. DHA-dFdC is a pancreatic candidate drug; KPC34, a small molecule for acute myeloid and acute lymphoblastic, are also in development. It is developing an antiviral platform to prevent replication of several viruses including the influenza virus, SARS, MERS, Ebolavirus and Marburg virus. The University of Texas and Wake Forest University Health Sciences have licensed it. Spherix Incorporated was the company’s former name. In March 2021, it changed its name from AIkido Pharma Inc. AIkido Pharma Inc. is located in New York, New York.

NASDAQ ended the session with AIkido Pharma dropping 11.69% to $0.41 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ slid 2.22% to $13,888.82, following the last session’s downward trend on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for AIkido Pharma is 2603430 which is 121.22% above its average volume of 1176840.

AIkido Pharma’s last close was $0.47, 61.16% under its 52-week high of $1.21.

AIkido Pharma’s Stock Yearly Top and Bottom Value

AIkido Pharma’s stock is valued at $0.41 at 17:33 EST, way under its 52-week high of $1.21 and way above its 52-week low of $0.36.

AIkido Pharma’s Moving Average

AIkido Pharma’s worth is under its 50-day moving average of $0.44 and way below its 200-day moving average of $0.70.

More news about AIkido Pharma.

4. FuboTV (FUBO) – -10.33%

NYSE ended the session with FuboTV falling 10.33% to $6.20 on Wednesday while NYSE slid 0.35% to $16,587.10.

Volume

Today’s last reported volume for FuboTV is 20601000 which is 71.93% above its average volume of 11981600.

FuboTV’s last close was $6.60, 89.4% below its 52-week high of $62.29.

FuboTV’s Sales

FuboTV’s sales growth is 134.7% for the current quarter and 68.6% for the next. The company’s growth estimates for the present quarter and the next is 61.8% and 73.4%, respectively.

FuboTV’s Revenue

Year-on-year quarterly revenue growth grew by 1541.1%, now sitting on 330.17M for the twelve trailing months.

FuboTV’s Stock Yearly Top and Bottom Value

FuboTV’s stock is valued at $6.20 at 17:33 EST, way under its 52-week low of $14.64.

FuboTV’s Moving Average

FuboTV’s value is way under its 50-day moving average of $27.97 and way below its 200-day moving average of $26.76.

More news about FuboTV.

5. Accolade (ACCD) – -9.42%

Accolade, Inc. creates and delivers technology-enabled solutions to help Americans understand, navigate, use, and benefit from the United States’ healthcare system. It offers cloud-based technology as well as multimodal support by a group of clinicians and health assistants. This includes nurses, doctor medical directors and behavioral specialists. The company also offers second opinion consultations and support for health care decisions. Employers can use the company to provide a one-stop shop for all their benefits, health and healthcare needs. Accolade, Inc. was established in 2007, and has its headquarters in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Accolade falling 9.42% to $16.05 on Wednesday while NASDAQ dropped 2.22% to $13,888.82.

Volume

Today’s last reported volume for Accolade is 276743 which is 72.26% below its average volume of 997739.

Accolade’s last close was $17.72, 68.05% below its 52-week high of $55.47.

The company’s growth estimates for the ongoing quarter and the next is a negative 131.2% and a negative 68.2%, respectively.

Accolade’s Revenue

Year-on-year quarterly revenue growth grew by 117.1%, now sitting on 275.5M for the twelve trailing months.

Accolade’s Stock Yearly Top and Bottom Value

Accolade’s stock is valued at $16.05 at 17:33 EST, way below its 52-week high of $55.47 and way higher than its 52-week low of $12.64.

Accolade’s Moving Average

Accolade’s worth is below its 50-day moving average of $17.60 and way under its 200-day moving average of $33.39.

More news about Accolade.

6. Celsius Holdings (CELH) – -9.18%

Celsius Holdings, Inc. markets, distributes, sells and promotes functional, calorie-burning, fitness drinks in the United States as well as internationally. It offers a variety of beverages, such as carbonated orange and wild berry, cola and grape, kiwi guava and watermelon. Celsius Heat is a nutritional supplement that contains carbonated flavorings such as orange jack’d and blueberry pomegranate. Blueberry pomegranate. strawberry dragonfruit. tangerine grapefruit. It distributes products via direct-store distribution distributors as well as retailers that include supermarkets and convenience stores as well as drug and nutritional stores and mass merchants. In January 2007, Celsius Holdings, Inc. was established. Celsius Holdings, Inc., was established in 2004. It is located in Boca Raton, Florida.

NASDAQ ended the session with Celsius Holdings sliding 9.18% to $51.55 on Wednesday while NASDAQ dropped 2.22% to $13,888.82.

Volume

Today’s last reported volume for Celsius Holdings is 1133610 which is 9.35% above its average volume of 1036640.

Celsius Holdings’s last close was $56.76, 48.5% under its 52-week high of $110.22.

Celsius Holdings’s Sales

Celsius Holdings’s sales growth is 151.4% for the ongoing quarter and 108.3% for the next. The company’s growth estimates for the ongoing quarter and the next is 100% and 400%, respectively.

Celsius Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 157.6%, now sitting on 245.68M for the twelve trailing months.

Celsius Holdings’s Stock Yearly Top and Bottom Value

Celsius Holdings’s stock is valued at $51.55 at 17:33 EST, way below its 52-week high of $110.22 and way higher than its 52-week low of $39.45.

Celsius Holdings’s Moving Average

Celsius Holdings’s worth is under its 50-day moving average of $53.65 and way under its 200-day moving average of $71.43.

More news about Celsius Holdings.

7. LendingTree (TREE) – -9.06%

LendingTree, Inc. operates an online platform for consumers in the United States through LendingTree, LLC, its subsidiary. The company operates in three segments: Home, Consumer, Insurance. Its Home segment provides purchase, refinance, reverse, and equity mortgages; lines of credit and brokerage services. The Consumer segment offers credit cards, personal, small-business, student and auto loans, deposit accounts, as well as other credit products such credit repair services and debt settlement. Its Insurance segment provides information and tools as well access to quotes products. This includes home and auto. Consumers are then matched up with lead aggregators in order to receive insurance offers. The company also owns CompareCards which is an online resource for side-by-side comparison shopping for credit cards; SimpleTuition which offers student loans marketing platforms; MagnifyMoney that provides editorial content and expert commentary; SnapCap that connects businesses owners and lenders; ValuePenguin that gives consumers an objective analysis and QuoteWizard.com that allows for comparison of insurance prices; Student Loan Hero that helps student loan borrowers to manage student loan debt. In January 2015, the company, formerly Tree.com, Inc., was changed to LendingTree, Inc. LendingTree, Inc. is located in Charlotte, North Carolina.

NASDAQ ended the session with LendingTree falling 9.06% to $113.39 on Wednesday while NASDAQ dropped 2.22% to $13,888.82.

Volume

Today’s last reported volume for LendingTree is 207704 which is 2.65% below its average volume of 213373.

LendingTree’s last close was $124.68, 50.13% under its 52-week high of $250.00.

LendingTree’s Sales

LendingTree’s sales growth is 19.2% for the present quarter and 1.6% for the next. The company’s growth estimates for the present quarter is a negative 261.5% and positive 72.2% for the next.

LendingTree’s Revenue

Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 1.1B for the twelve trailing months.

LendingTree’s Stock Yearly Top and Bottom Value

LendingTree’s stock is valued at $113.39 at 17:33 EST, way below its 52-week high of $250.00 and way higher than its 52-week low of $90.97.

LendingTree’s Moving Average

LendingTree’s value is under its 50-day moving average of $114.70 and way under its 200-day moving average of $145.79.

More news about LendingTree.

8. Cloudflare (NET) – -8.92%

NYSE ended the session with Cloudflare falling 8.92% to $109.70 on Wednesday, after four successive sessions in a row of losses. NYSE dropped 0.35% to $16,587.10, following the last session’s downward trend on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Cloudflare is 5537530 which is 9.15% below its average volume of 6095320.

Cloudflare’s Sales

Cloudflare’s sales growth is 60.6% for the ongoing quarter and 39.6% for the next. The company’s growth estimates for the present quarter and the next is a negative 100% and a negative 50%, respectively.

Cloudflare’s Revenue

Year-on-year quarterly revenue growth grew by 52.9%, now sitting on 530.57M for the twelve trailing months.

More news about Cloudflare.

9. Veracyte (VCYT) – -8.5%

Veracyte, Inc. is a company that provides genomic diagnostics services in the United States as well as internationally. Afirma Genomic Sequencing Classifier, and Xpression Atlas are tools that can be used to diagnose benign thyroid nodules in patients who have indeterminate cytopathology results. The company is currently developing a nasal swab to detect early stage lung cancer; Percepta Genomic Atlas, which provides genomic profiling information from small tumor samples; Envisia Classifier; LymphMark; for subtyping lymphoma tests. Veracyte, Inc. is a biopharmaceutical partner with Johnson & Johnson, Acerta Pharma, Loxo Oncology, Inc., and Bayer AG. Calderome, Inc. was the company’s former name. In March 2008, Veracyte, Inc. took over that title. Veracyte, Inc., was founded in 2006. It is located in South San Francisco, California.

NASDAQ ended the session with Veracyte dropping 8.5% to $27.01 on Wednesday, following the last session’s downward trend. NASDAQ fell 2.22% to $13,888.82, following the last session’s downward trend on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for Veracyte is 537438 which is 36.41% below its average volume of 845237.

Veracyte’s last close was $27.01, 53.41% under its 52-week high of $57.97.

Veracyte’s Sales

Veracyte’s sales growth is 69.8% for the present quarter and 21.4% for the next. The company’s growth estimates for the present quarter is 63.6% and a drop 76.9% for the next.

Veracyte’s Revenue

Year-on-year quarterly revenue growth grew by 95%, now sitting on 219.51M for the twelve trailing months.

Veracyte’s Stock Yearly Top and Bottom Value

Veracyte’s stock is valued at $27.01 at 17:33 EST, way under its 52-week high of $57.97 and way above its 52-week low of $21.45.

Veracyte’s Moving Average

Veracyte’s worth is under its 50-day moving average of $27.54 and way under its 200-day moving average of $38.81.

More news about Veracyte.

10. ADiTx Therapeutics (ADTX) – -8.32%

ADiTx Therapeutics, Inc. is a biotech firm that develops technology to improve the immune system’s health through immune reprogramming, monitoring, and other means. AditxtScore, which allows people to monitor, understand and manage their immune systems, is developed by the company. Apoptotic DNA immunotherapy (a nucleic-based technology) mimics how the body induces tolerance towards its own tissue. ADiTx Therapeutics is currently developing ADi products to aid organ transplantation. These include skin grafting and autoimmune diseases as well as allergies. ADiTx Therapeutics is licensed by Loma Linda University, and Leland Stanton Junior University. ADiTx Therapeutics, Inc., was established in 2017. It is located in Mountain View, California.

NASDAQ ended the session with ADiTx Therapeutics sliding 8.32% to $0.43 on Wednesday while NASDAQ fell 2.22% to $13,888.82.

Volume

Today’s last reported volume for ADiTx Therapeutics is 328266 which is 57.3% below its average volume of 768855.

ADiTx Therapeutics’s last close was $0.47, 88.23% below its 52-week high of $3.95.

The company’s growth estimates for the present quarter and the next is 151.1% and 123.9%, respectively.

ADiTx Therapeutics’s Stock Yearly Top and Bottom Value

ADiTx Therapeutics’s stock is valued at $0.43 at 17:33 EST, way below its 52-week high of $3.95 and way above its 52-week low of $0.32.

ADiTx Therapeutics’s Moving Average

ADiTx Therapeutics’s worth is above its 50-day moving average of $0.41 and way under its 200-day moving average of $1.30.

More news about ADiTx Therapeutics.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here